Cell therapy in the multimodality treatment of a patient with dilated cardiomyopathy. A case report
https://doi.org/10.18087/cardio.2555
- Р Р‡.МессенРТвЂВВВВВВВВжер
- РћРТвЂВВВВВВВВнокласснРСвЂВВВВВВВВРєРСвЂВВВВВВВВ
- LiveJournal
- Telegram
- ВКонтакте
- РЎРєРѕРїРСвЂВВВВВВВВровать ссылку
Full Text:
Abstract
We present a 13-years follow-up results in patient with dilated cardiomyopathy. We performed intracoronary infusion of bone marrow mononuclear fraction in patient with 4th heart failure functional class in 2005. We observed an improvement in symptoms (patient had 1st functional class of heart failure) during 10-years follow-up. In 2015 due to clinical worsening we performed 2nd and 3rd bone marrow mononuclear cells infusion with 9-month interval. We observed a signifcant improvement in symptoms, EF and LV sizes. We continue the follow-up.
About the Authors
S. A. Beliy
Academician Pavlov First St. Petersburg State Medical University
Russian Federation
Russian Federation
L. Tolstogo 6/8, St. Petersburg 197022
V. I. Lukashenko
Academician Pavlov First St. Petersburg State Medical University
Russian Federation
Russian Federation
L. Tolstogo 6/8, St. Petersburg 197022
V. V. Komok
Academician Pavlov First St. Petersburg State Medical University
Russian Federation
Russian Federation
L. Tolstogo 6/8, St. Petersburg 197022
G. G. Khubulava
Academician Pavlov First St. Petersburg State Medical University
Russian Federation
Russian Federation
L. Tolstogo 6/8, St. Petersburg 197022
References
1. Braunwald E. Cardiomyopathies: An Overview. Circulation Research. 2017;121(7):711-21. https://doi.org/10.1161/CIRCRESAHA.117.311812
2. Maron BJ. Contemporary Defnitions and Classifcation of the Cardiomyopathies: An American Heart Association Scientifc Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Commitee, Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups, and Council on Epidemiology and Prevention. Circulation. 2006;113(14):1807-16. https://doi.org/10.1161/CIRCULATIONAHA.106.174287
3. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Defnition and Classifcation of Cardiomyopathies. Circulation. 1996;93(5):841-2. https://doi.org/10.1161/01.CIR.93.5.841
4. McKenna WJ, Maron BJ, Tiene G. Classifcation, Epidemiology, and Global Burden of Cardiomyopathies. Circulation Research. 2017;121(7):722-30. https://doi.org/10.1161/CIRCRESAHA.117.309711
5. Merlo M, Stolfo D, Anzini M, Negri F, Pinamonti B, Barbati G et al. Persistent recovery of normal lef ventricular function and dimension in idiopathic dilated cardiomyopathy during long‐term follow‐up: does real healing exist? Journal of the American Heart Association. 2015;4(1):e001504. https://doi.org/10.1161/JAHA.114.000570
6. Moon J, Shim CY, Kim Y-J, Park S, Kang S-M, Chung N et al. Lef Atrial Volume as a Predictor of Lef Ventricular Functional Recovery in Patients with Dilated Cardiomyopathy and Absence of Delayed Enhancement in Cardiac Magnetic Resonance. Journal of Cardiac Failure. 2016;22(4):265-71. https://doi.org/10.1016/j.cardfail.2015.12.011
7. Matsumura Y, Hoshikawa-Nagai E, Kubo T, Yamasaki N, Kitaoka H, Takata J et al. Prediction of lef ventricular reverse remodeling afer therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and β blockers in patients with idiopathic dilated cardiomyopathy. Cardiovascular Ultrasound. 2015;13(1):14. https://doi.org/10.1186/s12947-015-0009-4
8. McNamara DM, Starling RC, Cooper LT, Boehmer JP, Mather PJ, Janosko KM et al. Clinical and Demographic Predictors of Outcomes in Recent Onset Dilated Cardiomyopathy. Journal of the American College of Cardiology. 2011;58(11):1112-8. https://doi.org/10.1016/j.jacc.2011.05.033
9. Di Lenarda A, Pinamonti B, Mestroni L, Salvi A, Sabbadini G, Gregori D et al. Te natural history of dilated cardiomyopathy: a review of the Heart Muscle Disease Registry of Trieste. Italian Heart Journal. Supplement: Ofcial Journal of the Italian Federation of Cardiology. 2004;5(4):253-66. PMID: 15346692
10. Merlo M, Caiffa T, Gobbo M, Adamo L, Sinagra G. Reverse remodeling in Dilated Cardiomyopathy: Insights and future perspectives. IJC Heart & Vasculature. 2018;18:52-7. https://doi.org/10.1016/j.ijcha.2018.02.005
11. Martin-Rendon E. Meta-Analyses of Human Cell-Based Cardiac Regeneration TerapiesResponse to Martin-Rendon: What Can Systematic Reviews Tell Us About Cell Terapies for Ischemic Heart Disease? Circulation Research. 2016;118(8):1264-72. https://doi.org/10.1161/CIRCRESAHA.115.307540
12. Fisher SA, Doree C, Mathur A, Martin-Rendon E. Meta-Analysis of Cell Terapy Trials for Patients with Heart Failure. Circulation Research. 2015;116(8):1361-77. https://doi.org/10.1161/CIRCRESAHA.116.304386
13. Fisher SA, Doree C, Mathur A, Taggart DP, Martin-Rendon E. Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. Cochrane Database of Systematic Reviews. 2016, https://doi.org/10.1002/14651858.CD007888.pub3
14. Beliy S. A., Komok V. V. Cell therapy of chronic heart failure: State of the art. Kardiologiia. 2018,58 (S4):46-54. [Russian]. https://doi.org/10.18087/cardio.2442
15. Caforio ALP, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal. 2013;34(33):2636- 48. https://doi.org/10.1093/eurheartj/eht210
16. Krejci J, Mlejnek D, Sochorova D, Nemec P. Inflammatory Cardiomyopathy: A Current View on the Pathophysiology, Diagnosis, and Treatment. BioMed Research International. 2016;2016:4087632. https://doi.org/10.1155/2016/4087632
17. Sánchez-Trujillo L, Vázquez-Garza E, Castillo EC, García-Rivas G, Torre-Amione G. Role of Adaptive Immunity in the Development and Progression of Heart Failure: New Evidence. Archives of Medical Research. 2017;48(1):1-11. https://doi.org/10.1016/j.arcmed.2016.12.008
18. Ismahil MA, Hamid T, Bansal SS, Patel B, Kingery JR, Prabhu SD. Remodeling of the Mononuclear Phagocyte Network Underlies Chronic Inflammation and Disease Progression in Heart Failure: Critical Importance of the Cardiosplenic Axis. Circulation Research. 2014;114(2):266-82. https://doi.org/10.1161/CIRCRESAHA.113.301720
19. Van Linthout S, Tschöpe C. Inflammation - Cause or Consequence of Heart Failure or Both? Current Heart Failure Reports. 2017;14(4):251-65. https://doi.org/10.1007/s11897-017-0337-9
20. Rock KL, Lai J-J, Kono H. Innate and adaptive immune responses to cell death: Immunological reaction to cell death. Immunological Reviews. 2011;243(1):191-205. https://doi.org/10.1111/j.1600-065X.2011.01040.x
21. Bolli R. Repeated Cell Terapy: A Paradigm Shif Whose Time Has Come. Circulation Research. 2017;120(7):1072-4. https://doi.org/10.1161/CIRCRESAHA.117.310710
22. Tokita Y, Tang X-L, Li Q, Wysoczynski M, Hong KU, Nakamura S et al. Repeated Administrations of Cardiac Progenitor Cells Are Markedly More Effective Tan a Single Administration: A New Paradigm in Cell Terapy. Circulation Research. 2016;119(5):635- 51. https://doi.org/10.1161/CIRCRESAHA.116.308937
23. Guo Y, Wysoczynski M, Nong Y, Tomlin A, Zhu X, Gumpert AM et al. Repeated doses of cardiac mesenchymal cells are therapeutically superior to a single dose in mice with old myocardial infarction. Basic Research in Cardiology. 2017;112(2):18. https://doi.org/10.1007/s00395-017-0606-5
24. Tang X, Nakamura S, Li Q, Wysoczynski M, Gumpert AM, Wu W et al. Repeated Administrations of Cardiac Progenitor Cells Are Superior to a Single Administration of an Equivalent Cumulative Dose. Journal of the American Heart Association. 2018;7(4):pii: e007400. https://doi.org/10.1161/JAHA.117.007400
25. Wysoczynki M, Khan A, Bolli R. New Paradigms in Cell Terapy: Repeated Dosing, Intravenous Delivery, Immunomodulatory Actions, and New Cell Types. Circulation Research. 2018;123(2): 138-58. https://doi.org/10.1161/CIRCRESAHA.118.313251
26. Kubal C, Sheth K, Nadal-Ginard B, Galiñanes M. Bone marrow cells have a potent anti-ischemic effect against myocardial cell death in humans. Te Journal of Toracic and Cardiovascular Surgery. 2006;132(5):1112-8. https://doi.org/10.1016/j.jtcvs.2006.06.028
27. Duran JM, Makarewich CA, Sharp TE, Starosta T, Zhu F, Hoffman NE et al. Bone-Derived Stem Cells Repair the Heart Afer Myocardial Infarction Trough Transdifferentiation and Paracrine Signaling Mechanisms. Circulation Research. 2013;113(5):539- 52. https://doi.org/10.1161/CIRCRESAHA.113.301202
28. Hodgkinson CP, Bareja A, Gomez JA, Dzau VJ. Emerging Concepts in Paracrine Mechanisms in Regenerative Cardiovascular Medicine and Biology. Circulation Research. 2016;118(1):95-107. https://doi.org/10.1161/CIRCRESAHA.115.305373
29. Karantalis V, Balkan W, Schulman IH, Hatzistergos KE, Hare JM. Cell-based therapy for prevention and reversal of myocardial remodeling. American Journal of Physiology-Heart and Circulatory Physiology. 2012;303(3):H256-70. https://doi.org/10.1152/ajpheart.00221.2012
30. Alestalo K, Mietinen JA, Vuolteenaho O, Huikuri H, Lehenkari P. Bone Marrow Mononuclear Cell Transplantation Restores Inflammatory Balance of Cytokines afer ST Segment Elevation Myocardial Infarction. PLOS ONE. 2015;10(12): e0145094. https://doi.org/10.1371/journal.pone.0145094
31. Barile L, Cerisoli F, Frati G, Gaetani R, Chimenti I, Forte E et al. Bone marrow-derived cells can acquire cardiac stem cells properties in damaged heart. Journal of Cellular and Molecular Medicine. 2011;15(1):63-71. https://doi.org/10.1111/j.1582-4934.2009.00968.x
32. Yoon C-H, Koyanagi M, Iekushi K, Seeger F, Urbich C, Zeiher AM et al. Mechanism of Improved Cardiac Function Afer Bone Marrow Mononuclear Cell Terapy: Role of Cardiovascular Lineage Commitment. Circulation. 2010;121(18):2001-11. https://doi.org/10.1161/CIRCULATIONAHA.109.909291
33. Van den Akker F, Deddens JC, Doevendans PA, Sluijter JPG. Cardiac stem cell therapy to modulate inflammation upon myocardial infarction. Biochimica et Biophysica Acta (BBA) - General Subjects. 2013;1830(2):2449-58. https://doi.org/10.1016/j.bbagen.2012.08.026
34. Marguti I, Yamamoto GL, da Costa TB, Rizzo LV, de Moraes LV. Expansion of CD4+ CD25+ Foxp3+ T cells by bone marrowderived dendritic cells: In vitro Treg expansion by dendritic cells. Immunology. 2009;127(1):50-61. https://doi.org/10.1111/j.1365-2567.2008.02927.x
35. Chen B, Frangogiannis NG. Immune cells in repair of the infarcted myocardium. Microcirculation. 2017;24(1):e12305. https://doi.org/10.1111/micc.12305
36. Lu Y, Wang Y, Lin M, Zhou J, Wang Z, Jiang M et al. A systematic review of randomised controlled trials examining the therapeutic effects of adult bone marrow-derived stem cells for non-ischaemic dilated cardiomyopathy. Stem Cell Research & Terapy. 2016;7(1):186. https://doi.org/10.1186/s13287-016-0441-x
37. Jiao R, Liu Y, Yang W-J, Zhu X-Y, Li J, Tang Q-Z. Effects of stem cell therapy on dilated cardiomyopathy. Saudi Medical Journal. 2014;35(12):1463-8. PMID: 25491210
38. Marquis-Gravel G, Stevens L-M, Mansour S, Avram R, Noiseux N. Stem Cell Terapy for the Treatment of Nonischemic Cardiomyopathy: A Systematic Review of the Literature and Meta-analysis of Randomized Controlled Trials. Canadian Journal of Cardiology. 2014;30(11):1378-84. https://doi.org/10.1016/j.cjca.2014.03.026
39. Poglajen G, Zemljič G, Frljak S, Cerar A, Andročec V, Sever M et al. Stem Cell Terapy in Patients with Chronic Nonischemic Heart Failure. Stem Cells International. 2018;2018:6487812. https://doi.org/10.1155/2018/6487812
Review
For citations:
Beliy S.A., Lukashenko V.I., Komok V.V., Khubulava G.G. Cell therapy in the multimodality treatment of a patient with dilated cardiomyopathy. A case report. Kardiologiia. 2019;59(4S):59-64. (In Russ.) https://doi.org/10.18087/cardio.2555
Views:
1039
ISSN 0022-9040 (Print)
ISSN 2412-5660 (Online)
ISSN 2412-5660 (Online)
Email this article 
Post a Comment 
